What are the common side effects of eculizumab?

Eculizumab is a humanized monoclonal antibody directed against C5 of the complement cascade and thereby inhibits the formation of C5a and C5b-9 membrane attack ... Sep 21, 2024 ... Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and myasthenia gravis. 2. How ... Mar 18, 2025 ... How is Soliris administered in myasthenia gravis? · 900 mg weekly for the first four weeks · 1,200 mg in the fifth week · 1,200 mg every other ... SOLIRIS (eculizumab) is an FDA-approved prescription medicine used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) This medication is given by a healthcare provider as an infusion through the vein to stop the body's immune system from attacking itself. Soliris (eculizumab) ... Paroxysmal Nocturnal Hemoglobinuria (PNH). SOLIRIS is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce ... Mar 10, 2025 ... FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children ... This landmark ... Jan 1, 2022 ... Soliris® (eculizumab) is unproven and not medically necessary for treatment of Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). Soliris 300 mg concentrate for solution for infusion. Active Ingredient: eculizumab. Company: Alexion Pharma UK Ltd. See contact details. Mar 30, 2022 ... What Are Warnings and Precautions for Eculizumab? · Discontinue if being treated for serious meningococcal infection · Supplement dose with ...